Centre For Respiratory Research, Rayne Institute, University College London, 5 University Street, London WC1E 6JJ, UK.
Thorax. 2010 Apr;65(4):362-9. doi: 10.1136/thx.2009.128025.
Recent research suggests that mesenchymal stem cells (MSCs) are able to migrate specifically to tumours and their metastases throughout the body. This has led to considerable excitement about the possibility of modifying these cells to express anticancer molecules and using them as specific targeted anticancer agents. However, there are concerns that systemically delivered MSCs may have non-desirable effects, and there are also many unanswered questions including the mechanism of tumour homing. This review investigates the different MSC-delivered anticancer agents, addresses the questions and concerns, and tries to place this potential therapy in future cancer management.
最近的研究表明，间充质干细胞（MSCs）能够在全身范围内特异性迁移到肿瘤及其转移部位。这使得人们对修饰这些细胞以表达抗癌分子并将其用作特异性靶向抗癌药物的可能性产生了极大的兴趣。然而，人们担心全身性给予的 MSCs 可能会产生不理想的效果，并且仍有许多悬而未决的问题，包括肿瘤归巢的机制。本综述调查了不同的 MSC 递送的抗癌药物，解决了相关的问题和担忧，并试图将这种潜在的治疗方法应用于未来的癌症管理中。
